xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06010901</url>
    </required_header>
    <id_info>
      <org_study_id>TQ2618-AK105-Ib-05</org_study_id>
      <nct_id>NCT06010901</nct_id>
    </id_info>
    <brief_title>A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.</brief_title>
    <official_title>A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This is a Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection as&#xD;
        monotherapy and a combination regimen (with Penpulimab injection ± Anlotinib hydrochloride&#xD;
        capsules) in the treatment of advanced colorectal cancer. 75 participants will be enrolled in&#xD;
        the study. Objective response rate (ORR) as assessed by Response Evaluation Criteria In Solid&#xD;
        Tumors (RECIST) version 1.1 is the primary endpoint.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 2023</start_date>
    <completion_date type="Anticipated">July 2025</completion_date>
    <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Objective response rate (ORR)</measure>
      <time_frame>From first administration until disease progression or withdrawal due to other reasons, estimated to not exceed 8 months.</time_frame>
      <description>According to RECIST 1.1 or Modified RECIST 1.1 for immune based therapeutics, (iRECIST) criteria, the proportion of subjects whose confirmed tumor volume reduction reached the pre-specified value and maintained the minimum time-frame requirements, i.e., the proportion of subjects with complete response (CR) and partial response (PR).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Overall survival (OS)</measure>
      <time_frame>Baseline up to death, estimated to not exceed 12 months</time_frame>
      <description>The time from randomization to death from any cause.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Progress free survival (PFS)</measure>
      <time_frame>From randomization to the time of disease progression or death from any cause, estimated to not exceed 12 months.</time_frame>
      <description>The time from randomization to the first disease progression or death from any cause, whichever occurs first.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease control rate (DCR)</measure>
      <time_frame>From first administration to the time of disease progression or withdrawal from any cause, estimated to not exceed 12 months.</time_frame>
      <description>Percentage of subjects with complete response, partial response, or stable disease as determined by RECIST 1.1 or iRECIST.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Duration of response (DOR)</measure>
      <time_frame>From first administration to the time of disease progression or death from any cause, estimated to not exceed 12 months.</time_frame>
      <description>From the time the tumor first assessed as complete or partial response to the time of first disease progression or death from any causes.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The incidence of adverse event (AE)</measure>
      <time_frame>From first administration to 28 days after withdrawal or the start time of the new anti-tumor treatment, whichever comes first.</time_frame>
      <description>The incidence and severity of adverse events as determined by the Common Terminology Criteria for Adverse Events (CTC AE).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Anti-drug antibodies (ADA)</measure>
      <time_frame>Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, 30 days and 90 days after the last dose. Each cycle is 21 days.</time_frame>
      <description>The occurrence of ADA</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Neutralizing antibodies (NaB)</measure>
      <time_frame>Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, 30 days and 90 days after the last dose. Each cycle is 21 days.</time_frame>
      <description>The occurrence of neutralizing antibodies</description>
    </secondary_outcome>
    <number_of_arms>3</number_of_arms>
    <enrollment type="Anticipated">75</enrollment>
    <condition>Colorectal Cancer</condition>
    <arm_group>
      <arm_group_label>TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TQB2618 injection combined with Penpulimab injection and Anlotinib hydrochloride capsules, 3 weeks as a treatment cycle.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>TQB2618 injection+Penpulimab injection</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TQB2618 injection combined with Penpulimab injection, 3 weeks as a treatment cycle.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>TQB2618 injection</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TQB2618 injection, 3 weeks as a treatment cycle.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>TQB2618 injection</intervention_name>
      <description>TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.</description>
      <arm_group_label>TQB2618 injection</arm_group_label>
      <arm_group_label>TQB2618 injection+Penpulimab injection</arm_group_label>
      <arm_group_label>TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Penpulimab injection</intervention_name>
      <description>Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.</description>
      <arm_group_label>TQB2618 injection+Penpulimab injection</arm_group_label>
      <arm_group_label>TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Anlotinib hydrochloride capsules</intervention_name>
      <description>Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.</description>
      <arm_group_label>TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS)&#xD;
               score: 0-1; Expected survival of more than 3 months;&#xD;
  &#xD;
            -  Histologically/cytologically confirmed metastatic colorectal cancer;&#xD;
  &#xD;
            -  The subjects should provide tumor tissues that meet the requirements for mismatch&#xD;
               repair protein detection and Programmed cell death-Ligand 1 (PD-L1) expression level&#xD;
               detection;&#xD;
  &#xD;
            -  Advanced colorectal cancer that progresses or is intolerant after receiving ≥3 lines&#xD;
               of standard therapy;&#xD;
  &#xD;
            -  Failure of treatment with at least one of these drugs (TAS-102, Regorafenib,&#xD;
               Fruquintinib);&#xD;
  &#xD;
            -  Confirmed presence of at least one measurable lesion according to Response Evaluation&#xD;
               Criteria In Solid Tumors 1.1 (RECIST 1.1) criteria;&#xD;
  &#xD;
            -  Body weight ≥40 kg and Body Mass Index (BMI) ≥18.5 kg/m^2.&#xD;
  &#xD;
            -  The function of the main organs is good, and the laboratory examination meets the&#xD;
               requirements;&#xD;
  &#xD;
            -  Female subjects of reproductive age should agree to use contraception during the study&#xD;
               period and for 6 months after the end of the study; Male subjects should agree that&#xD;
               contraception must be used during the study period and for 6 months after the end of&#xD;
               the study period.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Have had or are currently suffering from other malignant tumors within 3 years;&#xD;
  &#xD;
            -  Have any poorly controlled cardiovascular clinical symptoms or diseases;&#xD;
  &#xD;
            -  Patients with ulcerative colitis and Crohn's disease; Patients with active&#xD;
               inflammatory bowel disease within the first 4 weeks of enrollment;&#xD;
  &#xD;
            -  Symptoms of hematemesis and hematochezia occurred within 6 months before screening,&#xD;
               and the daily bleeding volume ≥ 2.5 mL;&#xD;
  &#xD;
            -  The presence of unmitigated toxic reactions of grade 1 or above as assessed per Common&#xD;
               Terminology Criteria for Adverse Events (CTC-AE) due to any treatment prior to first&#xD;
               administration, excluding hair loss;&#xD;
  &#xD;
            -  Patients who had received Programmed Death 1 (PD-1) or PD-L1 monoclonal antibody&#xD;
               treatment and experienced ≥ grade 3 immune-related adverse reactions or stopped immune&#xD;
               checkpoint inhibitor treatment due to immune-related adverse reactions;&#xD;
  &#xD;
            -  Active or uncontrolled severe infection (≥CTC AE grade 2 infection);&#xD;
  &#xD;
            -  Decompensated cirrhosis, active hepatitis;&#xD;
  &#xD;
            -  Poor diabetes control (fasting blood glucose &gt; 10 mmol/L);&#xD;
  &#xD;
            -  Patients with renal failure requiring hemodialysis or peritoneal dialysis;&#xD;
  &#xD;
            -  Have a clear history of neurological or psychiatric disorders, including epilepsy or&#xD;
               dementia, and require treatment;&#xD;
  &#xD;
            -  Had undergone a major surgical, open biopsy or significant traumatic injury within 4&#xD;
               weeks prior to the first dose of the study or expected to require major surgery during&#xD;
               the study treatment.&#xD;
  &#xD;
            -  Patients with arterial/venous thrombosis events, such as cerebrovascular accident,&#xD;
               deep vein thrombosis and pulmonary embolism, occurred within 6 months before the study&#xD;
               treatment;&#xD;
  &#xD;
            -  Ascites with clinical significance, including any ascites that can be found by&#xD;
               physical examination, ascites that have been treated in the past or still need to be&#xD;
               treated, and only those who show a small amount of ascites but no symptoms on imaging&#xD;
               can be included; Patients with an equal or greater amount of fluid in both pleural&#xD;
               cavities, or a large amount of fluid in one pleural cavity, or have caused respiratory&#xD;
               dysfunction and need drainage;&#xD;
  &#xD;
            -  The presence of unhealed wounds, ulcers or fractures;&#xD;
  &#xD;
            -  Have active tuberculosis, or have a history of active tuberculosis infection within 1&#xD;
               year prior to enrollment, or have a history of active tuberculosis infection more than&#xD;
               1 year prior to enrollment, but are not receiving treatment;&#xD;
  &#xD;
            -  There is a history of idiopathic pulmonary fibrosis, institutional pneumonia,&#xD;
               drug-induced pneumonia, radiation pneumonia requiring treatment or active pneumonia&#xD;
               with clinical symptoms, and interstitial lung disease requiring steroid hormone&#xD;
               therapy;&#xD;
  &#xD;
            -  Have a history of immunodeficiency, including Human Immunodeficiency Virus (HIV)&#xD;
               positive or other acquired or congenital immunodeficiency diseases, or have a history&#xD;
               of organ transplantation or hematopoietic stem cell transplantation;&#xD;
  &#xD;
            -  Imaging shows that the tumor has invaded large blood vessels or is not clearly&#xD;
               demarcated with blood vessels;&#xD;
  &#xD;
            -  Known central nervous system metastatic and/or cancerous meningitis;&#xD;
  &#xD;
            -  Have multiple factors that affect oral medication (such as inability to swallow,&#xD;
               chronic diarrhea, and intestinal obstruction);&#xD;
  &#xD;
            -  Allergic to the ingredients of the investigational pharmaceutical preparations or&#xD;
               excipients, or allergic to similar drugs;&#xD;
  &#xD;
            -  An active autoimmune disease requiring systemic treatment (e.g., disease-modifying&#xD;
               drugs, corticosteroids, or immunosuppressants) has occurred within 2 years prior to&#xD;
               initial medication;&#xD;
  &#xD;
            -  Have been diagnosed with immune deficiency or are receiving systemic glucocorticoid&#xD;
               therapy or any other form of immunosuppressive therapy (dose &gt; 10 mg/day prednisone or&#xD;
               other therapeutic hormone) and continue to use within 2 weeks before the first dose;&#xD;
  &#xD;
            -  History of live attenuated vaccine vaccination within 28 days before the first dose or&#xD;
               planned live attenuated vaccine vaccination during the study period;&#xD;
  &#xD;
            -  Have received systematic anti-tumor therapy and other interventional anti-tumor drug&#xD;
               clinical trials such as radical surgery, chemotherapy, radical radiotherapy or&#xD;
               immunotherapy, biotherapy, etc. within 4 weeks before the start of the study&#xD;
               treatment;&#xD;
  &#xD;
            -  Within 2 weeks prior to the first drug use, the treatment of Chinese patent drugs with&#xD;
               anti-tumor indications specified in the National Medical Products Administration&#xD;
               (NMPA) approved drug instructions.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>75 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Ruihua Xu, Doctor</last_name>
      <phone>+86 13922206676</phone>
      <email>13247323687@163.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Fuyang Cancer Hospital</name>
        <address>
          <city>Fuyang</city>
          <state>Anhui</state>
          <zip>236010</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Hesheng Qian, Bachelor</last_name>
        <phone>+86 13956814015</phone>
        <email>qianhesheng@soho.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Huai Nan First People's Hospital</name>
        <address>
          <city>Huainan</city>
          <state>Anhui</state>
          <zip>232007</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Yanshun Zhang, Bachelor</last_name>
        <phone>+86 18155498761</phone>
        <email>zhangyanshun2006@163.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Fujian Cancer Hospital</name>
        <address>
          <city>Fuzhou</city>
          <state>Fujian</state>
          <zip>350001</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Rongbo Lin, Bachelor</last_name>
        <phone>+86 13705919382</phone>
        <email>rongbo_lin@163.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>The First Affiliated Hospital of Xiamen University</name>
        <address>
          <city>Xiamen</city>
          <state>Fujian</state>
          <zip>361003</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Jiayi Li, Master</last_name>
        <phone>+86 13799792820</phone>
        <email>ljy778848@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Meizhou People's Hospital (Huangtang Hospital)</name>
        <address>
          <city>Meizhou</city>
          <state>Guangdong</state>
          <zip>514031</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Xiwen Huang, Bachelor</last_name>
        <phone>+86 13751952289</phone>
        <email>811253076@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Guangxi Medical University Cancer Hospital</name>
        <address>
          <city>Nanning</city>
          <state>Guangxi</state>
          <zip>530021</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Yongqiang Li, Master</last_name>
        <phone>+86 13457161928</phone>
        <email>lyq702702@126.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Hunan Cancer Hospital</name>
        <address>
          <city>Changsha</city>
          <state>Hunan</state>
          <zip>410000</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Zhenyang Liu, Doctor</last_name>
        <phone>+86 18673181133</phone>
        <email>1323081926@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Jilin Cancer Hospital</name>
        <address>
          <city>Changchun</city>
          <state>Jilin</state>
          <zip>130021</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>The First Hospital of China Medical University</name>
        <address>
          <city>Shenyang</city>
          <state>Liaoning</state>
          <zip>110002</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Xiujuan Qu, Doctor</last_name>
        <phone>+86 13604031355</phone>
        <email>qu_xiujuan@hotmail.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>The First Affiliated Hospital of Air Force Medical University</name>
        <address>
          <city>Xi'an</city>
          <state>Shaanxi</state>
          <zip>710000</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Hai chuan Su, Doctor</last_name>
        <phone>+86 18629190366</phone>
        <email>cntdgcp@163.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>The First Affiliated Hospital of Xi'an Jiao Tong University</name>
        <address>
          <city>Xi'an</city>
          <state>Shaanxi</state>
          <zip>710000</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Aili Suo, Doctor</last_name>
        <phone>+86 18991232561</phone>
        <email>ailisuo@mail.xjtu.edu.cn</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Affiliated Hospital of Jining Medical University</name>
        <address>
          <city>Jining</city>
          <state>Shandong</state>
          <zip>272007</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Junye Wang, Bachelor</last_name>
        <phone>+86 18678766866</phone>
        <email>18678766866@163.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Shanxi Cancer Hospital</name>
        <address>
          <city>Taiyuan</city>
          <state>Shanxi</state>
          <zip>030013</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Wenhui Yang, Doctor</last_name>
        <phone>+86 15835133400</phone>
        <email>yangwenhui-10012@163.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>The people's hospital of Leshan</name>
        <address>
          <city>Leshan</city>
          <state>Sichuan</state>
          <zip>614003</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Jing Tian, Master</last_name>
        <phone>+86 13981302204</phone>
        <email>5635452@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Mianyang central hospital</name>
        <address>
          <city>Mianyang</city>
          <state>Sichuan</state>
          <zip>621009</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Xiaobo Du, Doctor</last_name>
        <phone>+86 13550822229</phone>
        <email>Duxiaobo2005@126.com</email>
      </contact>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 21, 2023</study_first_submitted>
    <study_first_submitted_qc>August 23, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 25, 2023</study_first_posted>
    <last_update_submitted>August 23, 2023</last_update_submitted>
    <last_update_submitted_qc>August 23, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 25, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Colorectal Neoplasms</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06010901
  org study id: TQ2618-AK105-Ib-05
  nct id: NCT06010901
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  This is a Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection as
        monotherapy and a combination regimen (with Penpulimab injection ± Anlotinib hydrochloride
        capsules) in the treatment of advanced colorectal cancer. 75 participants will be enrolled in
        the study. Objective response rate (ORR) as assessed by Response Evaluation Criteria In Solid
        Tumors (RECIST) version 1.1 is the primary endpoint.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Objective response rate (ORR)
  time frame: From first administration until disease progression or withdrawal due to other reasons, estimated to not exceed 8 months.
  description: According to RECIST 1.1 or Modified RECIST 1.1 for immune based therapeutics, (iRECIST) criteria, the proportion of subjects whose confirmed tumor volume reduction reached the pre-specified value and maintained the minimum time-frame requirements, i.e., the proportion of subjects with complete response (CR) and partial response (PR).
  measure: Overall survival (OS)
  time frame: Baseline up to death, estimated to not exceed 12 months
  description: The time from randomization to death from any cause.
  measure: Progress free survival (PFS)
  time frame: From randomization to the time of disease progression or death from any cause, estimated to not exceed 12 months.
  description: The time from randomization to the first disease progression or death from any cause, whichever occurs first.
  measure: Disease control rate (DCR)
  time frame: From first administration to the time of disease progression or withdrawal from any cause, estimated to not exceed 12 months.
  description: Percentage of subjects with complete response, partial response, or stable disease as determined by RECIST 1.1 or iRECIST.
  measure: Duration of response (DOR)
  time frame: From first administration to the time of disease progression or death from any cause, estimated to not exceed 12 months.
  description: From the time the tumor first assessed as complete or partial response to the time of first disease progression or death from any causes.
  measure: The incidence of adverse event (AE)
  time frame: From first administration to 28 days after withdrawal or the start time of the new anti-tumor treatment, whichever comes first.
  description: The incidence and severity of adverse events as determined by the Common Terminology Criteria for Adverse Events (CTC AE).
  measure: Anti-drug antibodies (ADA)
  time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, 30 days and 90 days after the last dose. Each cycle is 21 days.
  description: The occurrence of ADA
  measure: Neutralizing antibodies (NaB)
  time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, 30 days and 90 days after the last dose. Each cycle is 21 days.
  description: The occurrence of neutralizing antibodies
  arm group label: TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules
  arm group type: Experimental
  description: TQB2618 injection combined with Penpulimab injection and Anlotinib hydrochloride capsules, 3 weeks as a treatment cycle.
  arm group label: TQB2618 injection+Penpulimab injection
  arm group type: Experimental
  description: TQB2618 injection combined with Penpulimab injection, 3 weeks as a treatment cycle.
  arm group label: TQB2618 injection
  arm group type: Experimental
  description: TQB2618 injection, 3 weeks as a treatment cycle.
  intervention type: Drug
  intervention name: TQB2618 injection
  description: TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
  arm group label: TQB2618 injection
  arm group label: TQB2618 injection+Penpulimab injection
  arm group label: TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules
  intervention type: Drug
  intervention name: Penpulimab injection
  description: Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.
  arm group label: TQB2618 injection+Penpulimab injection
  arm group label: TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules
  intervention type: Drug
  intervention name: Anlotinib hydrochloride capsules
  description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
  arm group label: TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 75 Years
  healthy volunteers: No
  last name: Ruihua Xu, Doctor
  phone: +86 13922206676
  email: 13247323687@163.com
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  country: China
  responsible party type: Sponsor
  mesh term: Colorectal Neoplasms